莫沙必利

莫沙必利
臨床資料
AHFS/Drugs.com国际药品名称
给药途径口服
ATC碼
  • 未分配
识别信息
  • (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide
CAS号112885-41-3  checkY
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.127.999 編輯維基數據鏈接
化学信息
化学式C21H25ClFN3O3
摩尔质量421.893 g/mol
3D模型(JSmol英语JSmol
  • Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
  • InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27) checkY
  • Key:YPELFRMCRYSPKZ-UHFFFAOYSA-N checkY

莫沙必利INN:mosapride)是一种胃肠动力药,选择性激动5-HT4受体;其主要代谢产物M1还具有5HT3受体的竞争性拮抗作用[1],可加速人体整个胃肠道的排空[2]

莫沙必利用来治疗胃炎胃食管反流病功能性消化不良肠易激综合征[3][4][5],也做為止吐劑,較不會誘發椎體外症候群[6]枸缘酸盐形式的莫沙必利,由大日本住友制药在1998年以加斯清为商品名上市销售。

參見

引用

  1. ^ Tack, J.; Camilleri, M.; Chang, L.; Chey, WD.; Galligan, JJ.; Lacy, BE.; Müller-Lissner, S.; Quigley, EM.; Schuurkes, J. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.. Aliment Pharmacol Ther. Apr 2012, 35 (7): 745–67. PMID 22356640. doi:10.1111/j.1365-2036.2012.05011.x. 
  2. ^ Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H. [Serotonin 5- HT4 receptor agonist (mosapride citrate)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. August 2006, 64 (8): 1491–4. PMID 16898619 (日语). 
  3. ^ Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs. 2008, 68 (7): 981–91. PMID 18457463. doi:10.2165/00003495-200868070-00007. 
  4. ^ Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.
  5. ^ Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent.Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.
  6. ^ 趙容萱. 台中11歲童春節旅遊中邪了?醫師找到原因了. 聯合報. 2023-02-01 [2023-02-01]. (原始内容存档于2023-03-24).